2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.23 Paydary

PP01.23 Paydary - Poster

Pdf Summary

The document discusses the potential role of polypharmacy, drug-drug interactions, and drug-substance interactions in causing targeted toxicities in non-small cell lung cancer (NSCLC) patients. The study collected real-world data from NSCLC patients taking tyrosine kinase inhibitors (TKIs) between 2012 to 2022, including their concomitant medications, substance use, and toxicity reports. Using a drug interaction tool, significant drug-drug interactions were identified at treatment start. The analysis revealed that toxicities associated with TKIs were linked to polypharmacy and the use of marijuana products. The study suggests that a significant portion of toxicities could be prevented by avoiding drug interactions. The findings highlight the need for future prospective studies to better understand the relationship between drug interactions and targeted toxicities in this patient population. <br /><br />Data from 153 NSCLC patients taking 15 different TKIs showed that 75.6% experienced any-grade toxicity. The median number of medications taken at the start of TKI treatment was six scheduled and two as needed. Specific drug combinations with TKIs were noted, along with FDA recommendations for each TKI based on drug interactions. The study emphasizes the importance of monitoring and avoiding certain drug combinations to minimize toxicities in NSCLC patients receiving TKIs. Further research is warranted to explore these interactions and their impact on treatment outcomes in this patient population.

Keywords

polypharmacy

drug-drug interactions

drug-substance interactions

non-small cell lung cancer

tyrosine kinase inhibitors

real-world data

toxicities

marijuana products

prospective studies

treatment outcomes